Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
0 hedge funds and large institutions have $0 invested in Biostar Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 6 closing their positions.
100% less funds holding
Funds holding: 6 → 0 (-6)
100% less capital invested
Capital invested by funds: $305K → $0 (-$305K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$239K |
| 2 |
Barclays
London,
United Kingdom
|
-$41K |
| 3 |
Morgan Stanley
New York
|
-$9K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| – | -$239K | -107,196 | Closed |
|
|
2
Barclays
London,
United Kingdom
| – | -$41K | -18,300 | Closed |
|
|
3
Morgan Stanley
New York
| – | -$9K | -3,950 | Closed |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$8K | -3,500 | Closed |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| – | -$7K | -3,250 | Closed |
|
6
UBS Group
Zurich,
Switzerland
| – | -$1K | -297 | Closed |
|
BSPM Hedge Fund Activity: Q3 2018 in Review
0 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q3 2018, worth a combined $0 — down 100% from $305K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BSPM and 0 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Acadian Asset Management, exiting entirely with an estimated $239K sold.
- 0 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q3 2018, down from 6 in Q2 2018.
- Funds reported $0 of Biostar Pharmaceuticals, Inc. stock for Q3 2018, down 100% quarter-over-quarter.
- 0 funds opened new Biostar Pharmaceuticals, Inc. positions in Q3 2018 and 6 closed out, a net change of -6 holders.
- The largest Biostar Pharmaceuticals, Inc. seller in Q3 2018 was Acadian Asset Management, an estimated $239K sold.
Based on aggregated 13F filings for Q3 2018.